HER2-Targeted Therapy in Upper GI Cancer

Opinion
Video

Sam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer

Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer

Tim Cortese
December 16th 2024
Article

Dostarlimab achieved a 100% clinical complete response rate in patients with dMMR/MSI-H advanced rectal cancer, a phase 2 study found.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer

Ariana Pelosci
November 21st 2024
Article

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Adrienne Bruce Shannon, MD;Sean Dineen, MD;Muhammad Talha Waheed, MD
April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Approaching End-of-Life Discussions With Directness and Compassion

Ariana Pelosci
October 30th 2024
Article

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

Ariana Pelosci
October 22nd 2024
Article

The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.